Finance & Capital Markets

  1. IL-2 Program Profits With Bonum's Drs. John Mulligan And Neela Patel 12/13/2023

    On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche.

  2. Episode 2: The Business Of Biotech: Allan Shaw 8/13/2020

    There are few better suited to advise the leaders of new and emerging biopharma companies on the building blocks of a biotech startup than Allan Shaw. That's why we chose Shaw to help us kick off our Business of Biotech podcast series with an overview of the episodes to come. In addition to his work on the financial front lines of several biotechs, Shaw holds multiple board of director roles with startup biopharma firms, and he advises dozens more in his role as special adviser. On this episode, we'll preview the series and absorb Shaw's to-the-point, practical advice on winning finances, building a pitch, assembling a biotech all-star team, leaving the incubator, navigating early regulatory considerations, and a whole lot more. The Business Of Biotech is produced by BioProcess Online and brought to you with the support of Cytiva.

  3. The Innovation Reduction Act With Allan Shaw 5/31/2023

    Allan Shaw posits that the Inflation Reduction Act (IRA) will stifle momentum in the biopharma industry and suggests its impact will ultimately cost patients and payers more. Tune in to learn why.

  4. BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty 2/26/2025

    On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms.

  5. Resilient Biopharma Leadership With Ambrx's Dan O'Connor 5/17/2023

    Since Dan O'Connor stepped in as CEO at Ambrx late last year, the company's stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O'Connor is no stranger to overcoming adversity, which we discussed at lenght on this episode of the Business of Biotech.

  6. Embracing Biotech Chaos With Memo's Erik van den Berg 9/8/2024

    Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail.

  7. The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 3/4/2024

    In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.

  8. Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt 11/26/2025

    On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.

  9. Mission-Driven Dementia Funding with DDF's Jonathan Behr 6/9/2024

    If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner.

  10. Serving The Underserved With Gates MRI's Claire Wagner, M.D. 11/10/2024

    On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there.